Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

OBJECTIVES: This study sought to test 2 hypotheses: 1) fibroblast growth factor (FGF)-23 identifies patients with stable ischemic heart disease (SIHD) at high risk of cardiovascular events independent of clinical factors, renal function, and established cardiovascular biomarkers; and 2) FGF-23 ident...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Udell, Jacob A., Morrow, David A., Jarolim, Petr, Sloan, Sarah, Hoffman, Elaine B., O’Donnell, Thomas F., Vora, Amit N., Omland, Torbjørn, Solomon, Scott D., Pfeffer, Marc A., Braunwald, Eugene, Sabatine, Marc S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4213068/
https://ncbi.nlm.nih.gov/pubmed/24727254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacc.2014.03.026
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak